Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.
Choi Y, Syeda F, Walker JR, Finerty PJ Jr, Cuerrier D, Wojciechowski A, Liu Q, Dhe-Paganon S, Gray NS. Choi Y, et al. Among authors: gray ns. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70. doi: 10.1016/j.bmcl.2009.05.029. Epub 2009 May 13. Bioorg Med Chem Lett. 2009. PMID: 19553108 Free PMC article.
mTOR Mediated Anti-Cancer Drug Discovery.
Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. Liu Q, et al. Among authors: gray ns. Drug Discov Today Ther Strateg. 2009 Summer;6(2):47-55. doi: 10.1016/j.ddstr.2009.12.001. Drug Discov Today Ther Strateg. 2009. PMID: 20622997 Free PMC article.
Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS. Liu Q, et al. Among authors: gray ns. J Med Chem. 2010 Oct 14;53(19):7146-55. doi: 10.1021/jm101144f. J Med Chem. 2010. PMID: 20860370 Free PMC article.
Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Liu Q, et al. Among authors: gray ns. J Med Chem. 2011 Mar 10;54(5):1473-80. doi: 10.1021/jm101520v. Epub 2011 Feb 15. J Med Chem. 2011. PMID: 21322566 Free PMC article.
Development of ATP-competitive mTOR inhibitors.
Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, Gray NS. Liu Q, et al. Among authors: gray ns. Methods Mol Biol. 2012;821:447-60. doi: 10.1007/978-1-61779-430-8_29. Methods Mol Biol. 2012. PMID: 22125084 Free PMC article.
542 results